Vontobel Holding Ltd. Buys 31,687 Shares of Alkermes plc (NASDAQ:ALKS)

Vontobel Holding Ltd. increased its position in Alkermes plc (NASDAQ:ALKS) by 128.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 56,261 shares of the company’s stock after purchasing an additional 31,687 shares during the quarter. Vontobel Holding Ltd.’s holdings in Alkermes were worth $1,575,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ALKS. EFG Asset Management North America Corp. grew its position in shares of Alkermes by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 75,864 shares of the company’s stock worth $1,828,000 after buying an additional 359 shares in the last quarter. United Services Automobile Association grew its holdings in Alkermes by 3.1% during the 2nd quarter. United Services Automobile Association now owns 13,208 shares of the company’s stock worth $318,000 after acquiring an additional 400 shares in the last quarter. Signaturefd LLC increased its position in Alkermes by 51.2% during the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock valued at $34,000 after purchasing an additional 480 shares during the period. Fisher Asset Management LLC raised its holdings in shares of Alkermes by 1.0% in the 4th quarter. Fisher Asset Management LLC now owns 59,942 shares of the company’s stock valued at $1,663,000 after purchasing an additional 572 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its position in shares of Alkermes by 0.3% in the 3rd quarter. Handelsbanken Fonder AB now owns 220,600 shares of the company’s stock worth $6,175,000 after purchasing an additional 700 shares during the period. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Alkermes Price Performance

Shares of ALKS opened at $28.27 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.99 and a quick ratio of 2.61. The company’s fifty day moving average price is $27.76 and its 200-day moving average price is $25.83. Alkermes plc has a 1-year low of $22.01 and a 1-year high of $32.88. The firm has a market capitalization of $4.78 billion, a PE ratio of 11.17, a price-to-earnings-growth ratio of 0.56 and a beta of 0.46.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Wednesday, July 24th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. The business had revenue of $399.13 million for the quarter, compared to the consensus estimate of $393.30 million. During the same quarter in the previous year, the business earned $0.38 EPS. The company’s quarterly revenue was down 35.4% compared to the same quarter last year. On average, equities research analysts predict that Alkermes plc will post 2.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ALKS. Cantor Fitzgerald reissued an “overweight” rating and set a $48.00 price objective on shares of Alkermes in a report on Thursday, October 10th. Robert W. Baird boosted their price target on Alkermes from $37.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. JPMorgan Chase & Co. raised their price objective on Alkermes from $31.00 to $32.00 and gave the company a “neutral” rating in a research report on Thursday, July 25th. StockNews.com raised shares of Alkermes from a “hold” rating to a “buy” rating in a research report on Sunday, July 28th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $37.00 price objective on shares of Alkermes in a research report on Monday, October 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.70.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.